Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.
OncLive’s April Roundup of Key FDA Decisions in Oncology
Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC
FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer